Rituximab: new indication. Lymphoma maintenance therapy: inadequate follow-up.
Favourable short-term results need longer-term confirmation in terms of effects on survival; they also need to be weighed against the risk of serious adverse effects (infections, cardiac and gastrointestinal disorders).